What BIOEMTECH does

BIOEMTECH (legally BioEmission Technology Solutions S.A.) is a privately held Greek biotech founded in 2013 as BET Solutions and rebranded by 2017. Headquartered in Gerakas, Attica (Athens), Greece, with 11-50 employees (the company states a team of over 30 plus collaborators), it operates at the intersection of preclinical molecular imaging hardware and contract research services for the radiopharmaceutical field. It serves pharmaceutical and biotech drug developers, academic and research institutions, and nuclear medicine centers conducting radiopharmaceutical research, targeted radioligand/alpha therapy development, and molecular imaging studies.

The company's core technology is a portfolio of desktop-sized preclinical imaging scanners: β-eye (PET), γ-eye (SPECT/planar gamma), and φ-eye (optical fluorescence/bioluminescence). A central technical differentiator is the systems' ability to image alpha-emitting isotopes such as Ac-225 and Pb-212 — considered difficult or impossible on conventional preclinical systems — at clinically translational activity levels and scanning times, with simultaneous multi-animal imaging (up to four mice on the large field-of-view γ-eye). The portfolio is complemented by accessories (biomimetic mouse phantoms, vital-signs monitoring, rodent platforms), software tools, and an emerging GenAI-based tool that derives 3D dosimetry from 2D imaging data (developed under the Fortissimo Plus initiative using HPC resources from GRNET and CINECA). The φ-eye carries CE marking (2023) and the company is ISO 9001:2015 certified.

BIOEMTECH monetizes through three streams: hardware sales of its imaging systems, professional CRO services (in vitro assays, radionuclide therapy, molecular imaging, GLP toxicology, dosimetry, and disease/PDX models), and supporting software tools. Pricing is undisclosed and quote-based. Go-to-market combines direct enterprise field sales (Europe and major global accounts) with channel distributors for international markets — LabLogic (North America), Fusion Scientific Technologies (India), and Nuohai Life Science (China) — supported by scientific conferences, an annual preclinical workshop series, webinars, and content marketing. The company was substantially funded through EU research grants (Horizon 2020 projects including CUPIDO, nTrack, B2B, ERROR, VIVOIMAG) and a 2019 venture round from Metavallon VC, rather than large venture rounds.

Name

BIOEMTECH

Legal name

BioEmission Technology Solutions S.A.

Website

https://bioemtech.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

BIOEMTECH is a Greek biotech that builds desktop preclinical PET, SPECT, and optical imaging systems and provides CRO services for radiopharmaceutical research, serving pharma, biotech, and academic institutions developing targeted alpha and radioligand therapies.

Ownership category

akta.pro rank

Product category

Preclinical Imaging Systems (PET/SPECT/Optical) and Radiopharmaceutical CRO Services

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Diagnostic Imaging Centers (621512), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Preclinical imaging systems
• Radiopharmaceutical research
• Molecular imaging CRO
• PET SPECT scanners
• Targeted alpha therapy imaging

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Preclinical CRO Services: Contract research organization services including in vitro assays, radionuclide therapy studies, molecular imaging, GLP toxicology, dosimetry, and disease models for pharmaceutical and biotech clients
2. Imaging Systems: Sale of proprietary preclinical imaging systems (β-eye, γ-eye, φ-eye) to academic institutions, pharmaceutical companies, and contract research organizations
3. Software Tools: Software tools for imaging analysis, dosimetry, and data processing supporting the imaging systems and CRO services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

BIOEMTECH designs, manufactures, and sells proprietary desktop-sized preclinical molecular imaging systems (β-eye PET scanner, γ-eye SPECT/planar gamma imager, φ-eye optical imager) along with complementary accessories and software tools, while also operating as a preclinical contract research organization (CRO) offering molecular imaging, radionuclide therapy, GLP toxicology, dosimetry, disease models, and in vitro assay services for radiopharmaceutical research and drug development.

Product overview

BIOEMTECH offers a portfolio of preclinical imaging products (β-eye™ PET scanner, γ-eye™ SPECT system, and φ-eye™ optical imager) and provides comprehensive CRO preclinical services (molecular imaging, dosimetry, GLP toxicology, radionuclide therapy, disease models). The imaging systems are desktop-sized devices designed for radiopharmaceutical research, particularly alpha-emitter imaging (Ac-225, Pb-212). The products are complemented by accessories (phantoms, vital signs monitors, rodent platforms) and software tools, enabling end-to-end preclinical research workflows.

Differentiator

Problem solved

Functional benefit

Brands

• β-eye: PET (Positron Emission Tomography) preclinical imaging scanner for real-time dynamic imaging of positron-emitting isotopes
• γ-eye
• φ-eye
• smartHEALTH

Products and services

• β-eye™ (PET Imaging System) High-resolution PET (Positron Emission Tomography) imaging scanner for preclinical and translational research, providing real-time dynamic imaging with clinically translational activity levels and scanning times. Supports positron-emitting isotopes and customized configurations including in ovo imaging.
• γ-eye™ (SPECT Imaging System) Benchtop SPECT (Single Photon Emission Computed Tomography) and planar gamma imaging system for preclinical and translational research, capable of imaging therapeutic alpha emitters (Ac-225, Pb-212) and supporting simultaneous multi-animal imaging via a large field of view configuration.
• φ-eye™ (Optical Imaging System) Optical imaging system for in vivo fluorescence and bioluminescence imaging of biomolecules labeled with chromophores, used in preclinical drug discovery and molecular imaging applications; CE-marked for clinical use.
• Mouse Phantom (Fillable Biomimetic Phantom) Fillable biomimetic mouse phantom used for imaging calibration, validation, and quality control — including use with clinical SPECT/CT cameras — supplied to institutions such as Johns Hopkins University for prototype preclinical device development.
• Vital Signs Monitoring Vital signs monitoring equipment used during preclinical imaging procedures to track animal physiology.
• Rodent Procedure Platforms Platforms for handling and positioning rodents during preclinical imaging procedures.
• Molecular Imaging CRO Services Contract research services combining PET, SPECT, and optical imaging modalities for preclinical drug development.
• Radionuclide Therapy CRO Services Contract research services for preclinical radionuclide therapy development, with imaging capabilities for therapeutic isotopes including alpha emitters.
• Dosimetry CRO Services Preclinical dosimetry services providing absorbed-dose estimates, pharmacokinetic insights, and radiobiological modeling for radiopharmaceutical development, supported by a GenAI-based 3D dosimetry tool.
• GLP Toxicology CRO Services Regulatory-compliant Good Laboratory Practice (GLP) toxicology studies for preclinical drug development.
• In Vitro Assays & Stem Cell Therapy CRO Services Contract research services for in vitro assays and stem cell therapy studies supporting preclinical drug development.
• Disease Models CRO Services Preclinical disease model development and validation services for oncology and radiopharmaceutical research, including PDX models (e.g., via CERTIS Oncology partnership).
• Software Tools Subscription software tools for image analysis, data processing, dosimetry, and research support, including a GenAI-based 3D dosimetry module and the Pose2Xray synthetic X-ray image generator.

Quantifiable outcome

• Enables experiments at clinically translational activity levels and scanning times unique to preclinical imaging
• +2 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

13 partnerships are on record, tiered core and supporting.

• LabLogiccoreChannel Partner/ Reseller/ Distributor · 22 May 2026Strategic partnership focused on expanding sales and support for BIOEMTECH's innovative preclinical imaging solutions throughout North America. LabLogic provides dedicated sales and service support for BIOEMTECH's portfolio including β-eye, γ-eye and φ-eye systems, ensuring comprehensive local support and responsive service.
• CERTIS OncologycoreStrategic or Co-development Partner · 7 May 2026Strategic collaboration to offer integrated patient-derived xenograft (PDX) access for radiopharmaceutical preclinical studies. CERTIS supplies study-ready PDX avatars representing diverse tumor types for functional testing within BIOEMTECH's preclinical PET/SPECT imaging workflows, enabling sponsors to evaluate targeted radiotherapeutics with higher translational relevance.
• NorthStar Medical RadioisotopescoreStrategic or Co-development Partner · 17 February 2026Strategic supply agreement to ensure reliable supply of Actinium-225 (Ac-225) for preclinical radiopharmaceutical research. Agreement provides consistent access to Ac-225 starting Q1 2026, supporting preclinical studies and accelerating radiopharmaceutical development for BIOEMTECH's customers.
• Hamamatsu Photonics K.K.supportingTechnology or Integration · 13 November 2017Agreement for provision of Hamamatsu state-of-the-art optical sensors for integration into BIOEMTECH imaging systems.
• Fusion Scientific Technologies Pvt. Ltd.coreChannel Partner/ Reseller/ Distributor · 6 November 2017Official distribution agreement for distributing preclinical molecular imaging systems (β-eye, γ-eye, φ-eye) to the growing Indian market.
• Nuohai Life Science Co., LtdcoreChannel Partner/ Reseller/ Distributor · 5 October 2017Distribution partnership for preclinical molecular imaging systems to the emerging Chinese market.
• Foundation for Research and Technology – Hellas (FORTH)supportingStrategic or Co-development PartnerCollaboration within smartHEALTH project resulting in development and validation of pediatric radiation dosing software and enhancement of φ-eye preclinical imaging system with multi-angle imaging capabilities and improved data analysis tools.
• Ratio TherapeuticssupportingTechnology or IntegrationCollaboration at 1st BIOEMTECH User Meeting where Jacob Hestermann from Ratio Therapeutics presented on 225Ac in vivo imaging, demonstrating how γ-eye enables capture of RadioLigand Therapy dynamics in real time.
• GRNET – Greek Research & Technology NetworksupportingTechnology or IntegrationPartnership under Fortissimo Plus initiative for GenAI-based 3D dosimetry project, utilizing HPC resources from GRNET for enhanced dosimetry accuracy in preclinical research.
• AlethiasupportingTechnology or IntegrationPartnership under Fortissimo Plus initiative for GenAI-based tool for 3D dosimetry from 2D imaging in preclinical studies.
• CINECAsupportingTechnology or IntegrationUtilizing HPC resources from CINECA center for the GenAI-based 3D dosimetry project for preclinical studies.
• Phantech LLCsupportingTechnology or IntegrationCollaboration providing innovative phantom technology for BIOEMTECH workshops. Phantech supplied mouse restrainers and BioMouse fillable biomimetic mouse phantoms for animal preparation sessions.
• NuclearPharmsupportingTechnology or IntegrationCollaboration with Antonio Shegani, CEO of NuclearPharm and research associate at NCSR DEMOKRITOS, demonstrating high-resolution in vivo PET tomography with β-eye.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Bruker Corporation: Bruker is a leading life-science instrumentation company offering preclinical PET, SPECT, MRI and optical imaging systems through its Bruker BioSpin / Molecular Imaging division. It is the most established commercial competitor in preclinical nuclear imaging and operates across far broader applications than BIOEMTECH's radiopharmaceutical focus.
• Revvity (formerly PerkinElmer Life Sciences): Revvity operates the PerkinElmer legacy life-sciences franchise, including IVIS optical imaging and a broad preclinical imaging portfolio. It competes in fluorescence/bioluminescence and PET/SPECT preclinical imaging and has a much larger global sales and service footprint than BIOEMTECH.
• Siemens Healthineers (preclinical / Molecular Imaging): Siemens Healthineers sells preclinical and clinical PET/SPECT/CT systems (e.g., Inveon legacy line) and is a broad incumbent in nuclear medicine imaging. While its primary focus is clinical, its preclinical instruments overlap with BIOEMTECH's β-eye/γ-eye at larger academic and pharma customers.
• Charles River Laboratories: Charles River is a global preclinical CRO offering safety assessment, discovery and radiolabeled services. It competes with BIOEMTECH's CRO services in molecular imaging, dosimetry and GLP toxicology for radiopharmaceutical and general drug-development sponsors, though at much larger scale and scope.

Direct peers

• Mediso Medical Imaging Systems: Mediso is a Hungarian manufacturer of preclinical PET, SPECT, CT and multimodal imaging systems (nanoScan, AnyScan). It is one of the closest direct competitors to BIOEMTECH's β-eye and γ-eye in preclinical nuclear medicine imaging.
• Molecubes: Molecubes is a Belgian vendor of benchtop preclinical PET, SPECT and CT systems (β-CUBE, γ-CUBE, X-CUBE). It directly competes with BIOEMTECH in the desktop/cube-format preclinical imaging category and targets similar academic and CRO customers.
• Invicro (a Konica Minolta company): Invicro provides preclinical and clinical imaging CRO services, including PET and radiopharmaceutical analysis. It is a direct competitor to BIOEMTECH's molecular imaging and dosimetry CRO services for pharma/biotech sponsors.

Others

• LabLogic Systems: LabLogic is a UK-based vendor of radiodetection, chromatography and QC instruments for life-science and nuclear-medicine labs. It is now BIOEMTECH's North American distribution partner, but its broader PET/SPECT radio-TLC and dose-calibrator portfolio overlaps with end-customers BIOEMTECH serves and makes it both a channel and an adjacent technology peer.
• CERTIS Oncology Solutions: CERTIS Oncology provides patient-derived xenograft (PDX) and tumor model services for oncology drug development. It is a strategic partner of BIOEMTECH for PDX-based radiopharmaceutical studies, but its disease-model offerings also compete with BIOEMTECH's own CRO disease-model service line.
• NorthStar Medical Radioisotopes: NorthStar is a US radioisotope producer expanding into therapeutic isotopes including Actinium-225. It is a strategic Ac-225 supply partner to BIOEMTECH, but its broader isotope-production business shapes the supply ecosystem that BIOEMTECH's α-eye value proposition depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioemtech

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOEMTECH